EssilorLuxottica and Diesel announce a ten-year licensing agreement
ESSILORLUXOTTICA AND DIESELANNOUNCE A TEN-YEAR LICENSING AGREEMENT Charenton-le-Pont, France and Milan, Italy (18 June 2024) – EssilorLuxottica and Diesel announced...
DNA
Biobanking Market size is set to grow by USD 1.66 billion from 2024-2028, growing demand for personalized medicine to boost the market growth, Technavio
NEW YORK, June 19, 2024 /PRNewswire/ -- The global biobanking market size is estimated to grow by USD 1.66 billion from...
DNA Health & Wellness, the MENA Regions’ Largest Health Optimisation and Longevity Clinic Group, is Set to Expand into Abu Dhabi
With five pioneering & established clinics in Dubai, the new state-of-the-art clinic will open in Abu Dhabi in the third...
New England Biolabs® and Inorevia to partner on novel solutions for the preparation of challenging samples for next generation sequencing
IPSWICH, Mass. and PARIS, June 18, 2024 /PRNewswire/ -- New England Biolabs (NEB ®) and Inorevia announce a collaboration to...
Epigenica Unveils Breakthrough Epigenetics Platform, Launches First Commercial ChIP-seq Kit for High-throughput, Multiplex Genome-wide Profiling
EpiFinder™ Platform generates quantitative data at scale, with unprecedented speed and cost-efficiencyEpiFinder Genome generates 192 genome-wide profiles by simultaneously targeting up...
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
Partnership Will Aid Physicians in Precision Prescribing Decisions Based on Applied DNA's TR8™ Pharmacogenomic (PGx) Test STONY BROOK, NY /...
Prenetics Announces First Quarter 2024 Financial Results
First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S....
FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital
MINNEAPOLIS, MN, June 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), today announced...
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with...
Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial
The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for responder...
Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS)
Gap in non-oral prescriptions relative to AHS guidelines represents an opportunity to increase awareness of Tonix’s two FDA-approved non-oral treatments...
Genetic Technologies Expands Operational Capacity in North America
Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory,...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of...
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy...
Prenetics Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
~ Emphasizes Strong Cash Position, No Debt, and A Dedicated Management Team Focused on Delivering Growth and Value to Shareholders...
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses...
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements; Completes Steps it Believes are Required to Regain Compliance
MINNEAPOLIS, June 14, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), reports that it...
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other...
FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.
Acquisition expected to be synergistic with FOXO’s epigenetic technology in community health and addiction recovery settings as well as contribute...
Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...